Back to News
Market Impact: 0.3
Teva Wins FDA Approval For Once-Monthly Schizophrenia Treatment WELTRUZA
Source: Nasdaq
Healthcare & BiotechProduct LaunchesCompany Fundamentals
The FDA approved Teva Pharmaceuticals’ WELTRUZA (olanzapine) extended-release injectable suspension for treating adults with schizophrenia. The announcement provides no sales outlook or other commercial details.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.40
Ticker Sentiment
TEVA0.75
More News
- Teva wins FDA approval for monthly schizophrenia injection Weltruza
- Stocks making the biggest moves midday: T-Mobile, Verizon, AT&T, Crown Castle, Teva & more
- J&J Stock Ahead of Q3 Earnings: Should You Buy, Sell or Hold?
- Wall Street Week | Michigan Manufacturing, AI Debt Investments, Baby Bonds, Canadian Coal Fight
- Tesla drops 'Full Self-Driving' brand name in Europe after regulator pushback
- SpaceX makes big move into wireless. These once 'obsolete' tech stocks could benefit
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- Choosing an AI Copilot for Equity Research
- Weekly Update: Advanced Search Filters, Redesigned Ticker Dashboard, and Improved Search Experience